Montagna Laboratory - People
 |
Cristina Montagna, PhD Principle Investigator Professor of Radiation Oncology Division of Radiation Cancer Biology Co-leader, Genomic Instability and Cancer Genetics Rutgers Cancer Institute |
Profile of Cristina Montagna, PhD
Dr. Cristina Montagna a cancer biologist with extensive expertise in molecular cytogenetic and cell biology. Her laboratory has contributed significant work to the field of oncogene discovery, genomic instability in cancer, and age-related tissue degeneration. She obtained her PhD from the University of Milano where she trained with Prof.
Bandera Zeinomar Breast Cancer Release 012023
Impact of Cigarette Smoking and Alcohol Consumption on Black Breast Cancer Survivors
Investigators from Rutgers Cancer Institute, together with RWJBarnabas Health, found that a higher risk of mortality in Black breast cancer survivors is associated with a history of cigarette smoking along with regular alcohol consumption at the time of diagnosis. Learn more
Immune Monitoring and Flow Cytometry - Research Accomplishments
In the 2018 – 2022 period, the IMFC SR supported approximately 110 publications of which 30 in high-Impact Factor Journals:
Metabolomics - Research Accomplishments
In the 2018 – 2022 period the MSR SR supported approximately 240 publications, of which 50 in high-Impact Factor Journals. The MSR’s high Impact Factor publications are shown below:
Zhang Z, TeSlaa T, Xu X, Zeng X, Yang L, Xing G, Tesz GJ, Clasquin MF, Rabinowitz JD. Serine catabolism generates liver NADPH and supports hepatic lipogenesis. Nat Metab. 2021;3(12):1608-20. doi: 10.1038/s42255-021-00487-4. PubMed PMID: 34845393; PMCID: PMC8721747.
Organoid Development
Mission
Rutgers Cancer Institute is excited to announce a new organoid development shared resource (ODSR) that is being operationalized under the leadership of Faculty Director Michael Verzi.
Comprehensive Genomics - Research Accomplishments
Home | Research Accomplishments | Services & Requests | Equipment
In the 2018 – 2022 period the CGSR supported approximately 30 cancer-relevant publications, eight of which in high Impact Factor journals (IF>10) and 13 unique peer-reviewed research grant awards (three funded by the NCI).
Genome Editing - Research Accomplishments
In the 2018 – 2022 period, the GESR supported approximately 35 cancer-relevant publications, of which 8 were in high Impact Factor journals:
Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11(1):4810. doi: 10.1038/s41467-020-18444-2. PubMed PMID: 32968061; PMCID: PMC7511348.